These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8585865)

  • 1. Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs.
    D'Alonzo AJ; Sewter JC; Darbenzio RB; Hess TA
    Basic Res Cardiol; 1995; 90(5):424-34. PubMed ID: 8585865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
    Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cromakalim or glibenclamide on arrhythmias and dispersion of refractoriness in chronically infarcted in anesthetized dogs.
    D'Alonzo AJ; Sewter JC; Darbenzio RB; Hess TA
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Aug; 352(2):222-8. PubMed ID: 7477447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
    Sedgwick ML; Rasmussen HS; Cobbe SM
    Am J Cardiol; 1992 Dec; 70(18):1432-7. PubMed ID: 1442614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dispersion of ventricular repolarization in left ventricular hypertrophy: influence of afterload and dofetilide.
    Gillis AM; Mathison HJ; Kulisz E; Lester WM
    J Cardiovasc Electrophysiol; 1998 Sep; 9(9):988-97. PubMed ID: 9786080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J; Xue Y; Eto K; Ni C; Hashimoto K
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dofetilide promotes repolarization abnormalities in perfused Guinea-pig heart.
    Osadchii OE
    Cardiovasc Drugs Ther; 2012 Dec; 26(6):489-500. PubMed ID: 22918600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
    Kovács A; Gyönös I; Magyar J; Bányász T; Nánási PP; Spedding M; Szénási G
    J Cardiovasc Pharmacol; 2001 Jan; 37(1):78-88. PubMed ID: 11152377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine.
    Ozaki T; Uematsu T; Nagashima S; Nishimoto M; Nakashima M
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):478-87. PubMed ID: 1766473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
    Bashir Y; Thomsen PE; Kingma JH; Møller M; Wong C; Cobbe SM; Jordaens L; Campbell RW; Rasmussen HS; Camm AJ
    Am J Cardiol; 1995 Nov; 76(14):1040-4. PubMed ID: 7484858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
    Zuanetti G; Corr PB
    J Pharmacol Exp Ther; 1991 Jan; 256(1):325-34. PubMed ID: 1988663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
    Lu HR; Remeysen P; De Clerck F
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):132-6. PubMed ID: 7564354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antiarrhythmics on the electrical restitution in perfused guinea-pig heart are critically determined by the applied cardiac pacing protocol.
    Osadchii OE
    Exp Physiol; 2019 Apr; 104(4):490-504. PubMed ID: 30758086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
    Black SC; Butterfield JL; Lucchesi BR
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
    Yamamoto W; Hashimoto N; Matsuura J; Machida T; Ogino Y; Kobayashi T; Yamanaka Y; Ishiwata N; Yamashita T; Tanimoto K; Miyoshi S; Fukuda K; Nakaya H; Ogawa S
    J Cardiovasc Pharmacol; 2014 May; 63(5):421-7. PubMed ID: 24805146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.